107 results
Page 5 of 6
6-K
EX-99.3
76zkrobl7b965sk
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.1
mpphqqcjmf6az8bsw10
16 Jan 20
CONTROLLING INFLAMMATION JP Morgan Corporate Presentation January 2020
4:11pm
6-K
EX-99.1
wheyq2yz9md
14 Nov 19
Current report (foreign)
4:10pm
6-K
EX-99.4
k8b49sx
7 Nov 19
Current report (foreign)
7:00am
6-K
EX-99.1
uu4vc
7 Nov 19
Current report (foreign)
7:00am
6-K
EX-99.2
hjw8th4smr2fd52 mnu
14 Aug 19
Current report (foreign)
4:16pm
6-K
EX-99.1
bjdmmbr
14 Aug 19
Current report (foreign)
4:16pm
6-K
EX-99.1
591xgnvi 7v
18 Jul 19
InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
4:12pm
6-K
EX-99.1
dbwj0vh
13 Jun 19
Current report (foreign)
9:00am
6-K
EX-99.1
xpfyjnb qx8nq
5 Jun 19
Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
7:12am
6-K
EX-99.1
yyw8ifup2 4e8li6v9n
14 May 19
Current report (foreign)
8:09am
6-K
EX-99.1
m3t 1q8cegc
8 May 19
IFX-1 C5a Controlling inflammation Corporate Presentation May 2019
6:02am
20-F/A
p36tx59 2k
29 Mar 19
Annual report (foreign) (amended)
4:23pm
6-K
EX-99.1
23jrhswxr0 a74swpmbe
27 Feb 19
InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead CandidateIFX-1 in Pyoderma Gangraenosum
8:39am
6-K
EX-99.1
qekwg3f070cq3yg41q
6 Feb 19
InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
8:35am
6-K
EX-99.1
okdz8om
19 Dec 18
InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis
8:36am
6-K
EX-99.2
irhtjnuw
21 Nov 18
Current report (foreign)
8:34am
6-K
EX-99.3
n8vw i05oxjzqzix7a
21 Nov 18
Current report (foreign)
8:34am
6-K
EX-99.1
aqe 49fdtuc174mjyalm
8 Nov 18
InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa
8:52am